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Abstract
Lenalidomide is approved for the treatment of transfusion- dependent (TD) 
del(5q) myelodysplastic syndromes (MDS). However, few data are available in 
patients with transfusion- independent (TI) del(5q) MDS. In the first, observa-
tional, part of this 2- part study, we assessed the impact of transfusion depend-
ence on overall survival (OS) and non- leukemic death in untreated del(5q) 
MDS patients who were TD (n = 136), TI with hemoglobin (Hb) ≥10 mg/dL 
(n = 88), or TI with Hb <10 mg/dL (n = 96). In the second, interventional, 
part we assessed the quality- of- life (QoL) benefits and clinical efficacy of lena-
lidomide (10 mg/day) in 12 patients with TI del(5q) MDS and Hb <10 mg/
dL. In the untreated population, OS was significantly longer in TI than in TD 
patients (TI [Hb ≥10 g/dL], 108 months; TI [Hb <10 g/dL], 77 months; TD, 
44 months). Transfusion dependence also negatively impacted non- leukemic 
death rates. In the interventional part of the study, baseline Hb levels were 
found to correlate significantly with physical (R = 0.666, P = 0.035) and fatigue 
(R = 0.604, P = 0.049) QoL scores. Median physical QoL scores improved 
significantly after 12 weeks’ treatment with lenalidomide (+12.5; P = 0.020). 
Evaluable TI patients experienced early increases in Hb levels, and all attained 
an erythroid response. Our findings suggest that TI patients with moderate 
anemia may benefit from early treatment with lenalidomide.
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Introduction
Lenalidomide is approved in several countries for the treat-
ment of transfusion- dependent (TD) patients with anemia 
related to International Prognostic Scoring System (IPSS)- 
defined low- or intermediate- 1 (Int- 1)- risk myelodysplastic 
syndromes (MDS) and an isolated deletion of the long 
arm of chromosome 5 [del(5q)]. Treatment induces eryth-
roid and cytogenetic responses in a high proportion of 
patients [1–3], and erythroid responses appear to be as-
sociated with reduced risk of disease progression, improved 
survival, and quality- of- life (QoL) benefits [1, 4].
More than half of patients with del(5q) MDS are transfu-
sion independent (TI) at the time of diagnosis [5, 6]; how-
ever, most will ultimately become TD during the course 
of their disease [7]. Erythropoiesis- stimulating agents (ESAs) 
are widely used off label to treat anemia associated with 
MDS, with response rates ranging from a maximum of 
68% to a minimum of 19% [8]. A meta- analysis of 30 
studies published between 1990 and 2006, which included 
1314 MDS patients, identified the following as being predic-
tive of response to ESA treatment: low transfusion depend-
ence; a morphological diagnosis of refractory anemia (RA)/
RA with ringed sideroblasts; treatment with a fixed- dose 
versus a weight- based ESA regimen; shorter interval between 
diagnosis and treatment initiation; and lower baseline serum 
erythropoietin level [8]. However, response rates to ESAs 
are lower, and the duration of response is shorter, in pa-
tients with MDS with del(5q) than in MDS patients without 
this aberration (39% vs. 52%, P = 0.10, and 13 months 
vs. 27 months, P = 0.003, respectively, both according to 
International Working Group 2006 criteria) [9].
While transfusions may help to alleviate the occurrence 
and symptoms of anemia, prolonged transfusion depend-
ence is associated with reduced survival in patients with 
MDS [10–13], including those with del(5q) [6]. For example, 
in a report of 381 untreated patients with low- or Int- 1- 
IPSS risk del(5q) MDS, median survival among TD patients 
was 44 months, compared with 97 months in TI patients 
(P < 0.0001) [6]. Transfusion dependence is also associated 
with increased incidence and severity of comorbidities in 
patients with MDS [5, 11]. Of particular concern are cardiac 
events, as cardiac failure has been identified as the main 
cause of non- leukemic death in this population [5]. 
Furthermore, the risk of cardiac death is significantly in-
creased in patients with chronic anemia [14], and a hemo-
globin (Hb) level of about 10 g/dL has been suggested as 
the threshold for cardiac remodeling [15]. Consequently, 
active treatment options with the potential to prevent/delay 
transfusion dependence and improve QoL would be ad-
vantageous for patients with del(5q) MDS.
To date, patients with TI del(5q) MDS have typically 
been excluded from clinical trials with lenalidomide, partly 
as a result of concerns that lenalidomide may accelerate 
progression to acute myeloid leukemia (AML) [16–18]. 
However, the most comprehensive analysis available to 
date suggests that these concerns are unfounded [18]. 
Therefore, in view of the detrimental effects of prolonged 
transfusion dependence, we investigated the rationale for 
early intervention with lenalidomide in TI patients with 
anemia (defined as Hb <10 g/dL) and low or Int- 1 IPSS 
risk del(5q) MDS. We carried out a 2- step, retrospective 
analysis to: (i) assess the influence of transfusion depend-
ence and Hb levels on overall survival (OS) and non- 
leukemic death in an untreated cohort of patients with 
del(5q) MDS (observational study)[6] and (ii) evaluate 
the efficacy and QoL benefits of lenalidomide in a subset 
of Italian patients with TI del(5q) MDS enrolled in the 
phase 2 RevMDS trial (interventional study) [4].
Subjects and Methods
Observational part of study
The cohort of 381 patients has been described previously 
[6]. In brief, the cohort comprised patients with a docu-
mented diagnosis (and an exact date of diagnosis) by bone 
marrow examination and cytogenetic assessment of low 
or Int- 1 IPSS risk del(5q) MDS from nine centers and 
registries in Europe, the USA, and Australia. All patients 
were untreated and receiving best supportive care (defined 
as transfusions, chelation therapy, or ESAs). A total of 71 
patients who had received lenalidomide were initially 
 included, but were censored at the start of treatment.
Transfusion dependence was defined as a requirement 
for at least 4 units of red blood cell transfusions within 
8 weeks [6]. Patients were divided into three groups ac-
cording to transfusion status: TD, TI with baseline Hb 
values of ≥10 g/dL, and TI with baseline Hb values of 
<10 g/dL. 10 g/dL was established as the cut- off Hb level 
to confirm the impact of chronic anemia on survival. OS 
in each group was calculated by Kaplan–Meier analysis. 
For the event of non- leukemic death, cumulative incidences 
were estimated, considering progression to AML as a 
competing event. For both analyses, patients with no 
 observed events were censored at the last follow- up. Hazard 
ratios (HRs) for death (and non- leukemic death) were 
calculated using Cox proportional hazards models for TI 
patients (with Hb ≥ or <10 g/dL) versus TD patients.
Interventional part of study
The lenalidomide cohort comprised patients from the 
phase 2, multicenter, non- randomized, single- arm, open- 
label RevMDS lenalidomide trial (registered: EudraCT No. 
2008- 000547- 34) [4]. This trial enrolled a total of 45 
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patients with anemia and low or int- 1 IPSS risk del(5q) 
MDS with or without additional cytogenetic abnormalities, 
irrespective of transfusion status. The group comprised 
31 TD patients and 14 TI patients (based on current 
MDS criteria). The focus of the analysis presented here 
was the 12 TI patients with Hb <10 g/dL.
All patients received oral lenalidomide at a starting dose 
of 10 mg once daily for up to 12 months, or until unac-
ceptable toxicity, lack of response, disease progression, or 
relapse following erythroid improvement. The primary 
endpoint of the study was QoL. Secondary endpoints were 
efficacy and survival.
QoL during treatment was assessed using the MDS- 
specific, health- related QoL instrument QOL- E© version 
2 [19, 20], which was completed at baseline and at 8, 
12, 24, and 52 weeks’ follow- up. The QOL- E© question-
naire comprises two items concerning general perceptions 
of well- being, and 26 items addressing physical, functional, 
social, sexual, fatigue, and disease- specific domains. Higher 
scores in each domain (range, 0–100) reflect better QoL. 
Missing items were not substituted to score domains. This 
analysis focuses on changes from baseline to 12 weeks.
Hb was measured as part of a complete blood count 
performed weekly for the first 8 weeks, and every 15 days 
thereafter. Cytogenetic studies were carried out at a central 
laboratory at baseline and every 12 weeks during the study 
period.
Statistical analysis
Descriptive statistics were calculated, and parametric and 
non- parametric tests were applied. The prespecified criterion 
for significance was P < 0.05. Means and standard devia-
tions were used to describe normally distributed data. Non- 
normally distributed data were summarized using medians 
and interquartile ranges (IQRs) or frequencies (percentage), 
as appropriate. Between- group and within- patient compari-
sons were performed using paired t- tests and the Wilcoxon 
test respectively. Spearman’s rank correlation coefficient was 
used to investigate associations between pairs of continuous 
variables. Univariate Kaplan–Meier analysis was used to 
evaluate survival in the different subgroups.
Results
Observational part of study
This analysis was based on 320 patients, including 136 
TD patients, 88 TI patients with Hb ≥10 g/dL, and 96 
TI patients with Hb <10 g/dL. In total, 61 patients were 
excluded due to unknown transfusion status (n = 54) and 
missing baseline Hb data (all TI patients; n = 7). Baseline 
characteristics are shown in Table 1. Groups were well- 
matched in terms of age and gender distribution, and in 
the prevalence of neutropenia and thrombocytopenia. It 
Table 1. Observational part of study: baseline patient characteristics.
Characteristic TD, n = 136 TI with Hb ≥10 g/dL, n = 88 TI with Hb <10 g/dL, n = 96
Age: median (range), years 66 (28–91) 67 (33–95) 66.5 (31–91)
Gender, n (%)
Male 44 (32) 24 (27) 26 (27)
Female 92 (68) 64 (73) 70 (73)
IPSS status, n (%)
Low 50 (40) 56 (67) 40 (46)
Int- 1 76 (60) 28 (33) 47 (54)
Neutropenia, n (%) 48 (38) 29 (35) 35 (40)
Thrombocytopenia, n (%) 19 (14) 12 (14) 5 (5)
WHO classification, n (%)
RA 11 (8) 7 (8) 7 (7)
RARS 0 5 (6) 3 (3)
RCMD 18 (13) 11 (13) 7 (7)
5q syndrome 87 (64) 58 (66) 74 (77)
RAEB- 1 20 (15) 7 (8) 5 (5)
Karyotype [21], n (%)
Low risk1 113 (83) 67 (76) 79 (82)
Intermediate risk2 18 (13) 17 (19) 13 (14)
High risk3 5 (4) 4 (5) 4 (4)
Hb, hemoglobin; Int- 1, intermediate- 1; IPSS, International Prognosis Scoring System; RA, refractory anemia; RAEB- 1, RA with excess blasts- 1; RARS, 
RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; TD, transfusion- dependent; TI, transfusion- independent; WHO, 
World Health Organization.
1Isolated del(5q).
2All karyotoypes not defined as low- or high- risk karyotypes.
3del(5q) plus either chromosome 7 abnormality or ≥2 additional aberrations.
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is worthy of note, however, that RA with excess blasts- 1 
(RAEB- 1) was significantly more prevalent among TD than 
among TI patients, regardless of Hb level (P = 0.030). 
RAEB- 1 rates did not differ significantly between the two 
TI subgroups (P = 0.555).
OS and cumulative incidence of non- leukemic death at 
2 and 5 years’ follow- up are shown in Table 2. OS was 
significantly longer for both groups of TI patients than 
for TD patients (Fig. 1A), with the following medians: 
108 months in TI (Hb ≥10 g/dL) patients, 77 months in 
TI (Hb <10 g/dL) patients, and 44 months in TD patients. 
HRs were 0.44 (95% confidence interval [CI], 0.29- 0.68, 
P < 0.001) for TI (Hb ≥10 g/dL) versus TD, and 0.55 
(95% CI, 0.38–0.81, P = 0.002) for TI (Hb <10 g/dL) 
versus TD. In the TI subgroup, OS did not differ signifi-
cantly between patients with Hb ≥10 g/dL and those with 
Hb <10 g/dL (HR 0.80; 95% CI, 0.50–1.29; P = 0.355). 
In terms of non- leukemic death, survival was again sig-
nificantly longer for both TI groups than for TD patients 
(Fig. 1B). HRs were 0.34 (95% CI, 0.19–0.61, P < .001) 
for TI (Hb ≥10 g/dL) versus TD, and 0.42 (95% CI, 0.25–
0.71, P = .001) for TI (Hb <10 g/dL) versus TD. The 
risk of non- leukemic death was similar in the two TI 
patient groups (HR 0.81; 95% CI, 0.42–1.57; P = 0.533).
Interventional part of study
The baseline characteristics of the 45 patients enrolled in 
the phase 2 RevMDS lenalidomide trial have been reported 
previously [4]; those for the 12 TI patients with Hb <10 
g/dL are shown in Table 3. Among these patients, all of 
whom were female, median age was 68 years, and the 
majority were in the IPSS low- risk category.
On treatment with lenalidomide, TI patients experienced 
earlier improvements in Hb levels than TD patients. At 
12 and 24 weeks, Hb changes were significantly greater 
in TI than in TD patients (3.6 ± 1.6 vs. 1.9 ± 2.1 g/dL, 
P = 0.01, and 4.5 ± 1.6 vs. 3.1 ± 2.2 g/dL, P = 0.04, 
respectively), but the difference was no longer significant 
at 36 or 52 weeks (4.2 ± 1.9 vs. 3.1 ± 2.1 g/dL, P = 0.16, 
and 4.3 ± 2.3 vs. 3.5 ± 2.4 g/dL, P = 0.35 respectively). 
However, the frequency of cytogenetic responses was not 
significantly greater in TD than in TI patients (68% vs. 
58%, respectively, P = 0.606). One of the TI patients 
Figure 1. Observational part of study: (A) overall survival and (B) cumulative incidence of non- leukemic deaths by transfusion dependence and 
hemoglobin levels at diagnosis.
Table 2. Observational part of study: overall survival probability and cumulative incidence of non- leukemic deaths by transfusion dependence and 
hemoglobin levels at diagnosis.
TD, n = 136 TI with Hb ≥10 g/dL, n = 88 TI with Hb <10 g/dL, n = 96
2- year survival probability (95% CI), % 73.2 (64.8–80.9) 95.8 (89.9–99.2) 92.5 (85.8–97.2)
5- year survival probability (95% CI), % 41.3 (31.6–51.2) 81.6 (70.7–90.5) 65.4 (53.4- 76.4)
Survival: median (95% CI), months 44 (37–61) 108 (82–129) 77 (66–109)
2- year cumulative incidence of non- 
leukemic deaths (95% CI), %
21.3 (14.2–29.4) 2.8 (0.5–8.8) 5.2 (1.7–11.8)
5- year cumulative incidence of non- 
leukemic deaths (95% CI), %
46.0 (35.7–55.5) 8.3 (3.0–17.0) 19.7 (10.6–30.8)
CI, confidence interval; Hb, hemoglobin; TD, transfusion- dependent; TI, transfusion- independent.
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refused to continue the study because of drug- related 
myelosuppression, and was removed from subsequent 
analyses. All other patients were erythroid responders 
(defined as Hb increase ≥1.5 g/dL) [22].
Deaths occurred among TD patients only. There was 
no difference between the two groups in either disease 
progression (TD vs. TI: HR, 1.26; 95% CI, 0.32–4.88, 
P = 0.75), or ‘death or progression’ (HR, 2.85; 95% CI, 
0.83–9.81, P = 0.10) [4].
QoL changes in TI patients during treatment 
with lenalidomide
Individual QoL scores for the 12 TI patients at baseline 
and at week 12 are shown in Table 4. At baseline, 
nine patients reported poor QoL (score <60) in at 
least 1 domain. Baseline Hb levels were correlated 
with QOL- E© physical (R = 0.666, P = 0.035) and 
fatigue scores (R = 0.604, P = 0.049). Overall, QoL 
scores improved within 8 weeks, particularly in the 
physical (baseline median, 43.8; IQR, 25.00–62.50; 8- 
week median, 62.5; IQR, 46.88–78.13, P = 0.063) and 
fatigue (baseline median, 71.4; IQR, 66.67–80.95; 8- 
week median, 81.0; IQR, 76.19–86.90, P = 0.062) 
domains.
Changes at 12 weeks were significant for physical 
QoL scores (baseline median, 50.0; IQR, 31.25–62.50; 
12- week median, 62.5; IQR, 56.25–81.25, P = 0.020; 
Fig. 2); improvements were observed in five of six pa-
tients with poor baseline physical QoL. Baseline Hb 
levels in these patients ranged from 6.5 to 9.1 g/dL. 
The variation in physical scores from baseline to 
24 weeks were significantly correlated with changes in 
Hb levels (Fig. 3). No other significant differences were 
observed; however, the proportion of patients who re-
ported poor QoL decreased, and median scores increased 
in the functional, social, and fatigue domains after 
12 weeks. Interestingly, in the MDS- specific domain, 
the mean MDS- specific score was slightly lower at 
12 weeks than at baseline.
Table 3. Interventional part of study: baseline characteristics of TI 
 patients with hemoglobin <10 g/dL
TI with Hb <10 g/dL, 
n = 12
Age: mean (IQR), years 68 (64–74)
Female, n (%) 12 (100)
Disease duration: median (IQR), years 1.7 (0.6–2.7)
IPSS risk category, n (%)
 Low 10 (83)
 Int- 1 2 (17)
Karyotype, n (%)
 Isolated del(5q) 9 (75)
 del(5q) + 1 additional abnormality1 3 (25)
WHO classification, n (%)
 RA 2 (16.7)
 MDS with del(5q) 9 (75.0)
 RCMD 1 (8.3)
Hemoglobin level: median (IQR), g/dL 9.0 (7.7–9.5)
Platelet count: median (range), 100 × 109/L 3.6 (2.3–4.8)
ANC: median (range), 1 × 109/L 2.2 (1.4–3.6)
Charlson comorbidity index score
 0 5 (42)
 1 7 (58)
ANC, absolute neutrophil count; Int- 1, intermediate- 1; IPSS, International 
Prognosis Scoring System; IQR, inter- quartile range; MDS, myelodysplas-
tic syndromes; RA, refractory anemia; RCMD, refractory cytopenia with 
multilineage dysplasia; TI, transfusion- independent; WHO, World Health 
Organization.
1With the exception of chromosome 7 abnormality.
Table 4. Interventional part of study: changes in hemoglobin levels and quality of life scores between baseline and week 12 in individual patients with 
transfusion- independent MDS and hemoglobin <10 g/dL at baseline.
Case
Hb, g/dL QOL- E© physical QOL- E© functional QOL- E© social QOL- E© fatigue QOL- E© MDS specific
Baseline Week 12 Baseline Week 12 Baseline Week 12 Baseline Week 12 Baseline Week 12 Baseline Week 12
1 6.5 12.8 37.50 62.50 NA NA 50.00 NA 57.14 80.95 76.19 88.10
2 7.5 14.8 25.00 50.00 NA NA 50.00 100 76.19 NA NA NA
3 7.6 12.3 37.50 62.50 22.22 55.56 50.00 25.00 71.43 57.14 40.48 23.81
4 7.8 11.0 12.50 50.00 22.22 NA NA NA 52.38 71.43 28.57 35.71
5 8.5 11.8 62.50 62.50 33.33 33.33 25.00 25.00 80.95 80.95 23.81 30.95
6 8.9 NA 25.00 NA 33.33 NA 0 NA 66.67 NA 92.86 NA
7 9.0 12.0 NA 62.50 33.33 33.33 62.50 87.50 80.95 80.95 73.81 80.95
8 9.1 13.6 50.00 75.00 11.11 33.33 0 0 66.67 76.19 52.38 38.10
9 9.3 11.0 NA 87.50 100 100 100 NA 66.67 76.19 83.33 NA
10 9.6 12.6 62.50 87.50 100 100 100 100 85.71 85.71 NA 92.86
11 9.7 12.2 62.50 62.50 22.22 22.22 NA NA NA 80.95 NA NA
12 9.7 12.7 87.50 87.50 100 100 87.50 100 95.24 80.95 78.57 78.57
Hb, hemoglobin; MDS, myelodysplastic syndromes; NA, not available (value missing); QOL- E©, Quality of Life E version 2, an MDS- specific health- 
related quality of life instrument [16, 17].
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Discussion
The first, observational, part of this study assessed OS 
and the cumulative incidence of non- leukemic death ac-
cording to transfusion dependence and Hb levels in patients 
with del(5q) MDS managed by best supportive care only. 
This analysis builds on that previously reported by Germing 
et al. [6], who, using a multivariate analysis in the same 
cohort, found that transfusion dependence, anemia, throm-
bocytopenia, cytogenetic status, and age were all significant 
predictors of survival. Our subgroup analysis revealed that 
both OS and non- leukemic death rates were significantly 
improved in TI patients, regardless of Hb level, compared 
with TD patients. Other studies have demonstrated that 
transfusion dependence or transfusion intensity can nega-
tively impact OS in patients with MDS [10, 12, 23, 24]. 
One reason for the advantage of TI patients compared 
to TD patients might be that MDS is detected in an 
earlier stage in these patients and thus patients can be 
observed for a longer time.
Figure 2. Interventional part of study: box plot showing descriptive statistics for quality of life changes from baseline to 12 weeks in transfusion- 
independent patients during lenalidomide treatment. *indicates outlying data point. MDS, myelodysplastic syndromes.
Figure 3. Interventional part of study: changes of physical quality of life- E scores (x- axis) from baseline to 24 weeks significantly correlate with 
changes in hemoglobin levels (y- axis).
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There were fewer patients of Int- 1 IPSS risk status 
in the TI (Hb ≥10 g/dL) group than in the other co-
horts. This is to be expected, as these patients did not 
have anemia (defined as Hb <10 g/dL), which impacts 
on the number of cytopenias and, consequently, the 
IPSS score. Although the difference did not reach sta-
tistical significance, TI patients with Hb <10 g/dL had 
shorter OS than TI patients with Hb ≥10 g/dL, sug-
gesting that the severity of anemia in patients with TI 
del(5q) MDS is an important risk factor for early mor-
tality. Thus, it may be valuable to consider active treat-
ment options, rather than supportive care measures 
alone, in some TI patients, as a means of reducing the 
risk of disease progression and death while improving 
health- related QoL. One possible option is treatment 
with lenalidomide.
The interventional part of this study examined the ef-
fects of lenalidomide on Hb levels and QoL in TI patients 
with Hb <10 g/dL who were enrolled in the phase 2 
RevMDS trial. Although the sample size was small and 
data for some patients were incomplete, two points of 
interest emerged. Firstly, baseline scores for physical and 
fatigue QOL- E© were correlated with baseline Hb level. 
This is perhaps not unexpected, but indicates that patients 
perceive an impact of moderate anemia on these aspects 
of their QoL. Secondly, treatment with lenalidomide led 
to early and significant improvements in Hb levels, which 
correlated with a significant increase in QOL- E© physical 
scores. Noteworthy, in the cohort of TI patients, all 12 
patients were women. Women per se have a longer OS 
than men and may also have different response patterns 
to lenalidomide. Hence, the difference between patients 
<10 g/dL and TD patients could be in part attributable 
to this bias.
These data are consistent with previous reports describ-
ing an association between QoL and both Hb levels and 
transfusion dependence in patients with MDS [20, 25–27]. 
In a prospective observational study, Hb level was found 
to be the most important independent predictor of QoL 
[26]. In that study, the mean baseline Hb level for TI 
patients was 10.9 g/dL, and 10.3 g/dL for the total study 
population—somewhat higher than in the present analysis. 
Although the prospective study found significant concord-
ance between patients’ self- assessed QoL and physicians’ 
assessment of patients’ QoL (particularly using the QOL- E© 
tool), physicians were more likely to make systematic 
optimistic errors, tending to rate performance status as 
good when the patient reported poor QoL [26].
In conclusion, there is increasing recognition of the 
value of patient- reported outcomes in helping to guide 
treatment selections for patients with MDS [28]. Although 
the risks of adverse events, such as severe cytopenias, and 
benefits of early lenalidomide treatment, in terms of 
morbidity and mortality, should be further explored in 
a randomized setting, the present analysis suggests that 
patients with moderate anemia and poor physical QoL 
perceive a need for treatment before the onset of transfu-
sion dependence and may benefit from early treatment 
with lenalidomide.
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